Regenerative medicine in China: main progress in different fields.

Biao Cheng,Shu-Liang Lu,Xiao-Bing Fu

doi:10.1186/s40779-016-0096-z

Abstract

Regenerative medicine (RM) is an emerging interdisciplinary field of research and China has developed the research quickly and impressed the world with numerous research findings in stem cells, tissue engineering, active molecules and gene therapy. Important directions are induced differentiation of induced pluripotent stem and embryo stem cells as well as somatic stem cell differentiation potential and their application in trauma, burns, diseases of aging and nerve regeneration. The products ActivSkin and bone repair scaffolds have been approved and are applied in the clinic, and similar products are being studied. About 10 engineered growth-factor drugs for repair and regeneration have been approved and are used in the clinic. Gene therapy, therapeutic cloning and xenotransplantation are some of the strategies being studied. However, China needs to develop standards, regulations and management practices suitable for the healthy development of RM. Aspects that should be strengthened include sound administrative systems, laws, and technical specifications and guidelines; conservation of stem cell resources; emphasis on training and retention of talented stem cell researchers; and reasonable allocation of resources, diversification of investment and breakthroughs in key areas. Finally, broad and deep international cooperation is necessary.Electronic supplementary materialThe online version of this article (doi:10.1186/s40779-016-0096-z) contains supplementary material, which is available to authorized users.

Highlights

Since 2002, major foreign media has paid much attention to the progress of Regenerative Medicine (RM) in China included the Wall Street Journal, New Scientist and Times, and Journal of Applied Behavioral Analysis [1]
Many media has noted the significant progress in China and interpreted China’s policies on stem cells, tissue engineering and related areas
It noted that the Chinese government has invested a large amount of funding in RM represented by stem cell study, tissue engineering and clinical translational studies and the country has made great progress

Summary

Introduction

Since 2002, major foreign media has paid much attention to the progress of Regenerative Medicine (RM) in China included the Wall Street Journal, New Scientist and Times, and Journal of Applied Behavioral Analysis [1] (www.iias.nl/iiasn/29/IIASNL29_49.pdf ). Therapeutic applications The practice of stem cell clinical trials or treatment in China dates back to bone-marrow transplantation in the Before 2005, China had no stem cell therapies and activity factor clinical trials registered at ClinicalTrials.gov (http://www.clinicaltrials.gov/, Fig. 1) (Additional files 1 and 2).

Results

Conclusion